tradmap

LENZ LENZ Therapeutics, Inc.

$5.80 +0.00%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

LENZ Therapeutics, Inc. (LENZ) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $182 million. Shares last traded at $5.80, 88.6% below their 52-week high. Over the past year the stock is down 85.2%. Net profit margin is -660.1%, below the peer median of 5.3%.

Market Cap
$182M
Shares Out
31.4M
EPS (TTM)
$-6.37
P/E Ratio
P/S Ratio
9.55
P/B Ratio
0.83
Dividend / Share
Dividend Yield
52-Week High
$50.85
52-Week Low
$4.54
Volume
60,380
Avg Vol (3m)
41,715.873

Performance

1W
+20.33%
1M
+10.37%
3M
-19.67%
6M
-51.77%
YTD
-63.80%
1Y
-85.22%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
64.70
SMA (50)
$5.28
SMA (200)
$11.61
Price vs SMA50
+9.90%
Price vs SMA200
-50.05%
ATR (14)
$0.34

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$19M
Net Income
$-126M
Gross Margin
Operating Margin
-710.7%
Net Margin
-660.1%
Return on Equity
-57.5%
Return on Assets
-53.3%
Current Ratio
13.55
Debt / Equity
0.08
Revenue Growth (YoY)

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-2.34 2026-08-11
Q1 2026 $-1.32 2026-05-11
FY 2025 $-2.85 2026-03-24
Q3 2025 $-1.65 2025-11-05
Q2 2026 $-1.06 2026-08-11
Q1 2026 $-0.53 2026-05-11

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

LENZ vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
9.55 / 19.49 med
-51% discount
Net margin vs peers
-660.1% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.